| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00670046 Details | 2018-09-28 Interventional | 2 | 15 | Valproic Acid Prostatic Neopl… Prostate Cancer | The study was terminated per the PI decision. The study was designed to have power with 15 patients in each arm. The study was closed before we reached the target as the PI changed institution. | |||
| NCT02506985 Details | 2018-09-27 Interventional | 4 | 10 | Rivaroxaban Warfarin Embolism Pulmonary Embol… Thrombosis Venous Thrombos… | - - | |||
| NCT03091439 Details | 2018-09-26 Interventional | 2 | 1 | Dalbavancin Osteomyelitis | Business decision outlined by the corporation. - | |||
| NCT02985840 Details | 2018-09-26 Interventional | 4 | 127 | Dexamethasone Ondansetron Abdominal Pain Emergencies Nausea | Unable to access EMR for patients enrolled prior to 8/2015 for data collection Due to the transfer of electronic medical record systems, investigators were unable to access data from patients who were enrolled prior to August 2015 for the retrospective chart review component of this study. | |||
| NCT02012959 2013-002005-59 Details | 2018-09-26 Interventional | 3 | 9 | Tolvaptan Hyponatremia | Issues with participant recruitment & enrollment which made the trial impossible or highly
impracticable. Trial termination was not due to safety reasons. Issues with recruitment and enrollment made trial execution highly impracticable. This ultimately led to termination of the trial. The study was not terminated due to safety reasons. | |||
| NCT00939549 Details | 2018-09-26 Interventional | 2 | 0 | (T,G)-A-L Cyclophosphamid… Glatiramer Acet… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing Remit… | Study revised to retrospective chart review - | |||
| NCT02928419 Details | 2018-09-25 Interventional | 2 | 2 | Lenalidomide Myelodysplastic… Preleukemia Syndrome | "the study has been closed due to a low rate of patient enrollment (2 patients since the start
of the trial)" - | |||
| NCT02797522 Details | 2018-09-25 Interventional | 1 | 47 | Acetaminophen Entecavir Histamine Antag… Histamine H1 An… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Company decision to discontinue trial The ARC-521 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans. | |||
| NCT02680847 Details | 2018-09-25 Interventional | 4 | 32 | Naltrexone Oxycodone Moderate-severe… | The trial was terminated on 08FEB2018. Pfizer has decided to withdraw the New Drug Application
and has notified FDA. There are no efficacy or safety concerns. The study was terminated due to sponsor's decision instead of safety or efficacy reasons. Early termination led to small numbers of participants summarized or described and PK samples were not analyzed. | |||
| NCT00818259 Details | 2018-09-25 Interventional | 1 | [1 Refs] | 92 | Aprepitant Dexamethasone Fosaprepitant Ondansetron Vomiting Chemotherapy-In… | Study terminated early prior to completing targeted enrollment of participants <6 months of age
due to recruitment challenges. - | ||
| NCT03346538 Details | 2018-09-24 Interventional | 2 | 17 | Edaravone Cerebral Infarc… Ischemia Ischemic Stroke Stroke Acute Ischemic … | Business objectives have changed. - | |||
| NCT03680976 Details | 2018-09-21 Interventional | 2 | 0 | CXA-10 Asthma | The study will not take place at the University of Pittsburgh - | |||
| NCT02074904 Details | 2018-09-21 Interventional | 2 | 1 | Topiramate Alcohol Drinkin… | We terminated the study to run it as a sub-study of NCT02371889, which is a 13 week, placebo
controlled, double-blind, trial of topiramate in heavy drinkers. We terminated the study to run it as a sub-study of NCT02371889. We didn't enter results of the one subject randomized to study medication due to privacy concerns. | |||
| NCT01121536 2009-016648-38 Details | 2018-09-21 Interventional | 3 | 867 | Modafinil Depression Depressive Diso… | Business decision related to efficacy rather than tolerability limitations, not stopped for any
safety reasons. - | |||
| NCT00527943 2006-002809-31 Details | 2018-09-21 Interventional | 3 | [2 Refs] | 12944 | Vorapaxar Acute Coronary … Atherosclerosis Infarction Myocardial Infa… Myocardial Isch… | The trial was terminated at the request of the Data and Safety Monitoring Board. Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time. | ||
| NCT03385057 Details | 2018-09-20 Interventional | 1 | 0 | Acetaminophen Ibuprofen Hemorrhage Tonsillectomy W… | Study design flaws; research design needed to be reconfigured - | |||
| NCT02688907 Details | 2018-09-20 Interventional | 2 | 7 | Adavosertib Lung Neoplasms Small Cell Lung… Small Cell Lung… | change regimen - | |||
| NCT02415608 Details | 2018-09-20 Interventional | 2 | 4 | Ibrutinib Leukemia, Mast-… Mastocytosis Mastocytosis, S… Aggressive Syst… Mast Cell Leuke… Systemic Mastoc… | Slow accrual - | |||
| NCT01164098 Details | 2018-09-20 Interventional | 3 | 30 | Rituximab Proteinuria Recurrence FSGS | Voluntarily terminated by PI due to lack of feasibility. - | |||
| NCT02551731 Details | 2018-09-19 Interventional | 2 | 9 | Cannabidiol Spasm Spasms, Infanti… | Sponsor elected not to continue with study - |